摘要
目的探讨齐拉西酮与利培酮相比治疗精神分裂症的临床疗效及安全性。方法将100例精神分裂症患者随机分两组,观察组采用齐拉西酮治疗,对照组采用利培酮治疗。治疗8周后用简明精神病评定量表(BPRS)、阳性症状量表(SAPS)、阴性症状量表(SANS)进行疗效评定。结果 3个量表组内比较时,两组治疗后2、4、8周与治疗前比较,差异均有统计学意义(P<0.05)。各项评定时间组间比较时,两组差异无统计学意义(P>0.05)。观察组疗效优于对照组,两组不良反应有差异。结论齐拉西酮是一种较理想的治疗精神分裂症的药物,其疗效确切,安全性较好,值得临床推广应用。
Objective To explore the clinical curative effect and security of ziprasidone and risperidone in the treatment of schizophrenia.Methods 100 cases were divided into two groups randomly,as ziprasidone group(the observation group)and risperidone group(the control group).The clinical effect was assessed with BPRS,ASPS and SANS after 8 weeks.Results The effective rate of the observation group was better than the control group,the difference between the two groups wasn't significant(P0.05).The two groups after the treatment of 2,4,8 and before treatment,the difference was statistically.Conclusion Ziprasidone is a better drugs for the treatment of schizophrenia for its good efficacy and safety.
出处
《中国现代医药杂志》
2011年第6期70-72,共3页
Modern Medicine Journal of China